4D Molecular Therapeutics (FDMT) Amortization of Deferred Charges (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Amortization of Deferred Charges data on file, last reported at $786000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 11.81% year-over-year to $786000.0 in Q1 2026; TTM through Mar 2026 was $3.0 million, a 29.13% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 42.84% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $786000.0, up from $764000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for FDMT reached as high as $786000.0 in Q1 2026 and fell as low as $349000.0 in Q2 2023.
• Historically, Amortization of Deferred Charges has averaged $517117.6 across 5 years, with a median of $421000.0 in 2024.
• Across the five-year window, Amortization of Deferred Charges retreated 4.74% in 2022 and jumped 67.91% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $374000.0 in 2022, then rose by 9.89% to $411000.0 in 2023, then soared by 67.4% to $688000.0 in 2024, then climbed by 11.05% to $764000.0 in 2025, then advanced by 2.88% to $786000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $786000.0 in Q1 2026, $764000.0 in Q4 2025, and $742000.0 in Q3 2025.